Traders Sell Gilead Sciences (GILD) on Strength Following Insider Selling

Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Friday following insider selling activity. $114.77 million flowed into the stock on the tick-up and $195.93 million flowed out of the stock on the tick-down, for a money net flow of $81.16 million out of the stock. Of all stocks tracked, Gilead Sciences had the 18th highest net out-flow for the day. Gilead Sciences traded up $2.40 for the day and closed at $75.21Specifically, Director John Francis Cogan sold 5,833 shares of the firm’s stock in a transaction that occurred on Friday, April 20th. The stock was sold at an average price of $73.74, for a total value of $430,125.42. Following the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at approximately $4,310,250.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $68.13, for a total value of $3,406,500.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares in the company, valued at $209,006,625.06. The disclosure for this sale can be found here. Insiders have sold a total of 173,335 shares of company stock valued at $12,238,349 over the last ninety days. Company insiders own 1.30% of the company’s stock.

A number of research analysts recently weighed in on GILD shares. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the company a “hold” rating in a research note on Tuesday, April 17th. ValuEngine downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 2nd. Leerink Swann set a $72.00 price objective on Gilead Sciences and gave the company a “market perform” rating in a research note on Wednesday, May 2nd. Finally, Barclays cut their price objective on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $88.22.

The firm has a market capitalization of $92.75 billion, a price-to-earnings ratio of 8.78, a P/E/G ratio of -6.18 and a beta of 1.12. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The firm had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period in the previous year, the business posted $2.23 EPS. Gilead Sciences’s revenue for the quarter was down 21.8% compared to the same quarter last year. equities research analysts anticipate that Gilead Sciences, Inc. will post 5.77 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 28th. Stockholders of record on Friday, June 15th were issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend was Thursday, June 14th. Gilead Sciences’s payout ratio is presently 26.64%.

Several large investors have recently made changes to their positions in the company. Sanders Capital LLC boosted its stake in Gilead Sciences by 102.9% in the 4th quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after buying an additional 5,026,015 shares in the last quarter. CI Global Investments Inc. boosted its stake in Gilead Sciences by 5,461.1% in the 4th quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after buying an additional 3,257,969 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its stake in Gilead Sciences by 53.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 9,054,685 shares of the biopharmaceutical company’s stock valued at $648,679,000 after buying an additional 3,148,128 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Gilead Sciences by 12,545.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,070,327 shares of the biopharmaceutical company’s stock valued at $219,958,000 after buying an additional 3,046,047 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Gilead Sciences by 147.9% in the 1st quarter. Point72 Asset Management L.P. now owns 3,078,566 shares of the biopharmaceutical company’s stock valued at $232,093,000 after buying an additional 1,836,662 shares in the last quarter. 77.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply